QURE Insider Trading
Insider Ownership Percentage: 4.74%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $1,042,573.95
uniQure Share Price & Price History
Current Price: $13.00
Price Change: ▲ Price Increase of +3.61 (38.45%)
As of 04/17/2025 05:00 PM ET
uniQure Insider Trading History
uniQure Institutional Trading History
Data available starting January 2016
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease. In addition, it is developing AMT-162, which is in preclinical trial for the treatment of superoxide dismutase 1- amyotrophic lateral sclerosis; AMT-260 that is in preclinical trial to treat temporal lobe epilepsy; AMT-191, which is in preclinical trial for the treatment of fabry disease; AMT-161 that is in preclinical trial to treat amyotrophic lateral sclerosis caused by mutations; AMT-240, which is in preclinical trial to for the treatment of autosomal dominant Alzheimer's disease; and AMT-210 that is in preclinical trial to treat Parkinson's disease. The company was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on uniQure
Today's Range
Now: $13.00
52 Week Range
Now: $13.00
Volume
14,440,345 shs
Average Volume
1,738,888 shs
Market Capitalization
$703.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.42
Who are the company insiders with the largest holdings of uniQure?
uniQure's top insider shareholders include:
- Matthew C Kapusta (CEO)
- Christian Klemt (CFO)
- Ricardo Dolmetsch (Insider)
- Walid Abi-Saab (Insider)
- Pierre Caloz (COO)
- Jeannette Potts (Insider)
- Rachelle Suzanne Jacques (Director)
Learn More about top insider investors at uniQure.
Who are the major institutional investors of uniQure?
Which institutional investors are buying uniQure stock?
In the previous quarter, QURE stock was acquired by institutional investors including:
- Assenagon Asset Management S.A.
- Sanders Morris Harris LLC